Arcutis Biotherapeutics Inc’s recently made public that its Director Welgus Howard G. unloaded Company’s shares for reported $0.15 million on Apr 01 ’25. In the deal valued at $15.12 per share,10,000 shares were sold. As a result of this transaction, Welgus Howard G. now holds 121,944 shares worth roughly $1.58 million.
Then, Topper David Joseph sold 9,600 shares, generating $151,698 in total proceeds. Upon selling the shares at $15.80, the Chief Financial Officer now owns 182,774 shares.
Before that, Topper David Joseph bought 9,600 shares. Arcutis Biotherapeutics Inc shares valued at $151,698 were divested by the Officer at a price of $15.80 per share.
H.C. Wainwright initiated its Arcutis Biotherapeutics Inc [ARQT] rating to a Buy in a research note published on December 30, 2024; the price target was $19. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. Mizuho also remained covering ARQT and has increased its forecast on January 03, 2024 with a “Buy” recommendation from previously “Neutral” rating. Mizuho revised its rating on October 26, 2023. It rated ARQT as “a Neutral” which previously was an “a Buy”.
Price Performance Review of ARQT
On Monday, Arcutis Biotherapeutics Inc [NASDAQ:ARQT] saw its stock jump 2.78% to $12.94. Over the last five days, the stock has lost -9.51%. Arcutis Biotherapeutics Inc shares have fallen nearly -7.11% since the year began. Nevertheless, the stocks have risen 8.92% over the past one year. While a 52-week high of $17.75 was reached on 03/25/25, a 52-week low of $6.99 was recorded on 02/11/25. SMA at 50 days reached $14.20, while 200 days put it at $11.70.
Levels Of Support And Resistance For ARQT Stock
The 24-hour chart illustrates a support level at 12.65, which if violated will result in even more drops to 12.35. On the upside, there is a resistance level at 13.24. A further resistance level may holdings at 13.53. The Relative Strength Index (RSI) on the 14-day chart is 40.50, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -1.83, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 81.02%. Stochastics %K at 17.67% indicates the stock is a buying.
How much short interest is there in Arcutis Biotherapeutics Inc?
A steep rise in short interest was recorded in Arcutis Biotherapeutics Inc stocks on 2025-03-31, dropping by -5.14 million shares to a total of 14.63 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-28 was 19.77 million shares. There was a decline of -35.11%, which implies that there is a negative sentiment for the stock.
